ストックスクリーナーアプリを入手
0.30
59.18%
-0.435
Avenue Therapeutics Inc (ATXI) 最新ニュース
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Click Therapeutics Positions Over-the-Counter Digital Therapeutics as New Growth Avenue - TipRanks
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - PharmiWeb.com
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
MSN Money - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
AVENUE THERAPEUTICS, INC. 1Q 2026: Net loss $0.7M, Revenue $0— 10-Q Summary - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Avenue Therapeutics (OTC: ATXI) cuts Q1 loss but warns on going concern - Stock Titan
Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering - Business Wire
Executive pay and audits headline Monte Rosa (NASDAQ: GLUE) 2026 proxy - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics
Form S-1/A Hemab Therapeutics Holdi - StreetInsider
Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang - Seeking Alpha
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
Kailera Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Visa Inc. $V is Douglas Lane & Associates LLC’s 10th Largest Position - Defense World
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Stock List: Research Stocks from Around the World - GuruFocus
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - Yahoo Finance
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan
フォートレス・バイオテック、2025年度財務実績及び直近の企業ハイライトを報告 - Moomoo
Avenue Therapeutics Focuses on Neurologic Disease Therapies with ATX-04 and IV Tramadol as Key Product Candidates in 2026 - Minichart
Rare disease drug wins FDA nod as Fortress unit sells voucher for $205M - Stock Titan
ATXI: 2025 net loss narrowed to $2.9M as focus shifts to ATX-04 and IV tramadol amid funding challenges - TradingView
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Business Wire
Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - The Manila Times
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - marketscreener.com
Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - MarketScreener
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurology stocks rebound in 2025 after midyear slump - BioWorld MedTech
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Tangible book value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Net current asset value per share of Avenue Therapeutics, Inc. – LS:A40BWJ - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Halozyme Therapeutics, Inc. $HALO Shares Sold by Cary Street Partners Financial LLC - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
ATXI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avenue Therapeutics to develop add-on Pompe disease treatment - Pompe Disease News
Palvella Therapeutics Announces Proposed Public Offering - GlobeNewswire
Avenue Therapeutics licenses ATX-04 for Pompe disease treatment By Investing.com - Investing.com Australia
Avenue Therapeutics Licenses ATX-04 for Pompe Disease - TipRanks
Avenue Therapeutics (OTC: ATXI) licenses ATX-04 Pompe therapy from Duke - Stock Titan
0.37%
1.35%
大文字化:
|
ボリューム (24 時間):